Axona
  • Patient information website
  • Join our prescribing network
Axona® questions? Call us at 1-877-649-0004.
  • Search
  • Facebook
  • Twitter
  • YouTube
  • Home
  • DCGM
    • Normal cerebral glucose metabolism
    • DCGM in Alzheimer's disease
  • Ketone bodies
    • Ketone bodies background
    • Ketone bodies in Alzheimer’s disease
  • About Axona
    • Axona MOA
    • Efficacy
    • Safety
    • Clinical trials
    • Prescribing Axona
    • Alzheimer’s disease management
    • Pharmacy information
  • Case studies
    • Rosemary
    • Geraldine
  • FAQs
  • Videos
  • Resources

Home > News

News

Jan. 14 2014

Accera statement on FDA warning letter

Click here to read Accera's response to the recent FDA warning letter.

more ...

1 - 1 of 1

1

 

Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.

Axona should be used with caution in patients who are at risk for ketoacidosis, for example, patients with a history of alcohol abuse and poorly controlled diabetics; or those who have a history of inflammation of the gastrointestinal system, metabolic syndrome, and/or renal dysfunction. Axona contains caseinate and whey (dairy), and lecithin (soy). Contains: milk and soy.

Please see full prescribing information.

This website contains information relating to Alzheimer's disease and other specific medical conditions and their therapies. Such information is provided for educational purposes only, does not constitute medical advice, and is not meant to be a substitute for the advice of a doctor or other healthcare professional. You should not use this information for diagnosing a health problem or disease. In order for you to make informed healthcare decisions, you should always consult with a doctor or healthcare professional for your, or your loved one's, personal medical needs.

This site is intended for residents of the United States only. Axona is available in the United States only. The licensed material on this website is being used for illustrative purposes only; and any person depicted in the licensed material, if any, is a model.

Accera, Axona, and the Axona logo are trademarks or registered trademarks of Accera, Inc.
Patents issued: USP 6,835,750, EP 1292294, JP 3486778, and USP 8,426,468; and patents pending.
© 2023 Accera, Inc.   All rights reserved.  AC-14-743  04/14

  • Home
  • Diminished cerebral glucose metabolism
  • How ketone bodies can help in AD
  • About Axona
  • Dosage and administration
  • Company
  • Prescribe Axona
  • Case studies
  • Resources
  • References
  • Videos
  • News
  • FAQs
  • Contact us
  • HCP network
  • Patient site
  • Full prescribing information
  • Privacy Policy
  • Site map
  • Overview
    • Normal cerebral glucose metabolism
    • DCGM in Alzheimer's disease

Diminished cerebral glucose metabolism in Alzheimer’s disease

See how the brain changes in Alzheimer’s disease
  • Overview
    • Ketone bodies background
    • Ketone bodies in Alzheimer’s disease

Diminished cerebral glucose metabolism in Alzheimer’s disease

See how the brain changes in Alzheimer’s disease

See how ketone bodies can work together with glucose to fuel the brain in Alzheimer’s disease
Click here >

  • Overview
    • Axona MOA
    • Efficacy
    • Safety
    • Clinical trials
    • Prescribing Axona
    • Alzheimer’s disease management
    • Pharmacy information

Prescribing Axona

See how simple it is to prescribe and administer Axona
Axona starter kit

Order free Patient Starter Kits